Search
AM103
go.drugbank.com/drugs/DB05225ExperimentalAM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation
Categories: Heterocyclic Compounds, 2-RingDigitoxin
go.drugbank.com/drugs/DB01396ApprovedWithdrawnA cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexMolsidomine
go.drugbank.com/drugs/DB09282ApprovedWithdrawnInterestingly, it is being studied as being a preventive measure in cerebral infarction [A31932].
Categories: Heterocyclic Compounds, 1-RingProducts: MOLSIDOMIN 8 RET 1A PHARMA, MOLSIDOMIN 2 HEUMANNACA 125
go.drugbank.com/drugs/DB05489InvestigationalTo create ACA-125, a hybridoma cell was adapted to serum-free medium and antibody was produced in a hollow fiber cell culture system. Positive clinical results are now being reported. … ACA-125 mimics the tumor-associated antigen CA-125, which can be detected in about 80% of ovarian carcinomas.
Suzetrigine
go.drugbank.com/drugs/DB18927ApprovedInvestigationalSuzetrigine is a Na<sub>V</sub>1.8 voltage-gated sodium channel blocker with analgesic properties[A264948] Na<sub>V</sub>1.8 is abundantly expressed in peripheral sensory nerves to play a role in pain … signal transmission, making it a desirable therapeutic target for treatment of pain.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP2B6 InducersSynonyms: 2-Pyridinecarboxamide, 4-[[[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)tetrahydro-4,5-dimethyl-5-(trifluoromethyl)-2-furanyl]carbonyl]amino]-, 4-[(2R,3S,4S,5R)-3-(3,4-difluoro-2-methoxyphenyl)-4,5- dimethyl-5-(trifluoromethyl)oxolane-2- carboxamido]pyridine-2-carboxamideBuserelin
go.drugbank.com/drugs/DB06719ApprovedInvestigationalBuserelin is a synthetic peptide analog of the luteinizing hormone-releasing hormone (LHRH) agonist, which stimulates the pituitary gland's gonadotrophin-releasing hormone receptor (GnRHR).
Products: Suprefact Depot 2 Months, SUPREFACT INJECTABLE 1 mg/mlOCU400
go.drugbank.com/drugs/DB18277InvestigationalOCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).
Deslanoside
go.drugbank.com/drugs/DB01078ApprovedDeacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata.
Categories: Compounds used in a research, industrial, or household settingSynonyms: (3β,5β,12β)-3-{[β-D-glucopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-2,6-dideoxy-β-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide, 3-[(O-β-D-glucopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl-(1→4)-O-2,6-dideoxy-β-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3β,5β,12β-card-20(22)-enolideSafinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates, Cytochrome P-450 SubstratesSigvotatug Vedotin
go.drugbank.com/drugs/DB18377InvestigationalSigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.